Yang J, Hong W, Shi H, Wang Z, He C, Lei H
Signal Transduct Target Ther. 2025; 10(1):58.
PMID: 40000611
PMC: 11862015.
DOI: 10.1038/s41392-025-02154-6.
Kamelian K, Sievers B, Chen-Xu M, Turner S, Cheng M, Altaf M
Sci Adv. 2025; 11(7):eadq3342.
PMID: 39937891
PMC: 11817922.
DOI: 10.1126/sciadv.adq3342.
Jia S, Shao C, Cheng X, Pan H, Wang Z, Xia Y
Hum Vaccin Immunother. 2025; 21(1):2448405.
PMID: 39865693
PMC: 11776483.
DOI: 10.1080/21645515.2024.2448405.
Bdeir N, Luddecke T, Maass H, Schmelz S, Rand U, Jacobsen H
Nat Commun. 2025; 16(1):809.
PMID: 39827186
PMC: 11743207.
DOI: 10.1038/s41467-025-55871-5.
Turbawaty D, Komala D, Andriyoko B
J Multidiscip Healthc. 2025; 18():71-81.
PMID: 39816439
PMC: 11733193.
DOI: 10.2147/JMDH.S486098.
Ancestral SARS-CoV-2 immune imprinting persists on RBD but not NTD after sequential Omicron infections.
Wang Z, Li L, Du R, Chen X, Sun Y, Qin R
iScience. 2025; 28(1):111557.
PMID: 39807166
PMC: 11728909.
DOI: 10.1016/j.isci.2024.111557.
Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections.
Suntronwong N, Kanokudom S, Duangchinda T, Chantima W, Pakchotanon P, Klinfueng S
Sci Rep. 2025; 15(1):1454.
PMID: 39789099
PMC: 11718010.
DOI: 10.1038/s41598-024-84138-0.
Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2.
Hu H, Leng C, Shu Y, Peng L, Wu F, Liu J
J Virol. 2025; 99(2):e0130724.
PMID: 39772622
PMC: 11852929.
DOI: 10.1128/jvi.01307-24.
Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19.
Nakayama E, Shioda T
Pathogens. 2025; 13(12.
PMID: 39770368
PMC: 11728538.
DOI: 10.3390/pathogens13121109.
COVID-19 Reproduction Numbers and Long COVID Prevalences in California State Prisons.
Worden L, Wannier R, Archer H, Blumberg S, Kwan A, Sears D
medRxiv. 2025; .
PMID: 39763550
PMC: 11703306.
DOI: 10.1101/2024.12.14.24319022.
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.
Yang J, Hong W, Shi H, He C, Lei H, Zhou Y
Nat Commun. 2024; 15(1):10778.
PMID: 39738039
PMC: 11686202.
DOI: 10.1038/s41467-024-55087-z.
Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein.
Malladi S, Jaiswal D, Ying B, Alsoussi W, Darling T, Dadonaite B
bioRxiv. 2024; .
PMID: 39713327
PMC: 11661108.
DOI: 10.1101/2024.12.06.625234.
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity.
Roederer A, Cao Y, St Denis K, Sheehan M, Li C, Lam E
Cell Rep Med. 2024; 5(12):101850.
PMID: 39657661
PMC: 11722104.
DOI: 10.1016/j.xcrm.2024.101850.
Broad Neutralization Capacity of an Engineered Thermostable Three-Helix Angiotensin-Converting Enzyme 2 Polypeptide Targeting the Receptor-Binding Domain of SARS-CoV-2.
Cavazzini D, Levati E, Germani S, Ta B, Monica L, Bolchi A
Int J Mol Sci. 2024; 25(22).
PMID: 39596383
PMC: 11594380.
DOI: 10.3390/ijms252212319.
A Strategic Framework of SARS-CoV-2 Genomic Surveillance in Bangladesh.
Jubair M, Hossain M, Begum M, Moon S, Islam S, Karim M
Influenza Other Respir Viruses. 2024; 18(10):e70019.
PMID: 39440811
PMC: 11497173.
DOI: 10.1111/irv.70019.
Epidemiological and immunological characteristics of middle-aged and elderly people in housing estates after Omicron BA.5 wave in Jinan, China.
Zhao X, Li M, Zhang S, Li K, Wei W, Chen J
Heliyon. 2024; 10(19):e38382.
PMID: 39398026
PMC: 11467590.
DOI: 10.1016/j.heliyon.2024.e38382.
Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
Wang W, Bhushan G, Paz S, Stauft C, Selvaraj P, Goguet E
J Virol. 2024; 98(11):e0094824.
PMID: 39365051
PMC: 11578088.
DOI: 10.1128/jvi.00948-24.
Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates.
Cromer D, Reynaldi A, Mitchell A, Schlub T, Juno J, Wheatley A
Nat Commun. 2024; 15(1):8395.
PMID: 39333473
PMC: 11436652.
DOI: 10.1038/s41467-024-52194-9.
Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses.
Liang Z, Li C, Gong X, Ye G, Jiang Y, Shi H
PLoS Pathog. 2024; 20(9):e1012599.
PMID: 39325829
PMC: 11460674.
DOI: 10.1371/journal.ppat.1012599.
Comment on "Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis".
Sharifan A
Hum Vaccin Immunother. 2024; 20(1):2404290.
PMID: 39312724
PMC: 11421839.
DOI: 10.1080/21645515.2024.2404290.
